ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $21,133.86 in Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider Sarina Tanimoto sold 2,343 shares of the stock in a transaction that occurred on Friday, March 22nd. The shares were sold at an average price of $9.02, for a total transaction of $21,133.86. Following the transaction, the insider now owns 1,745,082 shares in the company, valued at approximately $15,740,639.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Sarina Tanimoto also recently made the following trade(s):

• On Thursday, March 14th, Sarina Tanimoto sold 444 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.00, for a total transaction of $3,996.00.
• On Wednesday, February 28th, Sarina Tanimoto sold 98,778 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.02, for a total transaction of $890,977.56.
• On Monday, February 26th, Sarina Tanimoto sold 700 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.01, for a total transaction of $6,307.00.

ARS Pharmaceuticals Stock Performance

Shares of SPRY stock opened at $10.22 on Friday. ARS Pharmaceuticals, Inc. has a one year low of $2.55 and a one year high of $11.27. The company’s fifty day moving average price is $7.84 and its 200-day moving average price is $5.83.

Analyst Upgrades and Downgrades

Several research firms have weighed in on SPRY. SVB Leerink upgraded shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $6.00 to $18.00 in a research report on Tuesday, March 5th. William Blair upgraded shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 20th. Wedbush reiterated an “outperform” rating and issued a $19.00 price target on shares of ARS Pharmaceuticals in a research report on Monday, March 11th. Finally, Leerink Partnrs upgraded shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 5th.

Institutional Trading of ARS Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Nisa Investment Advisors LLC raised its position in shares of ARS Pharmaceuticals by 22,300.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 5,600 shares of the company’s stock valued at $31,000 after purchasing an additional 5,575 shares during the period. AJOVista LLC purchased a new position in ARS Pharmaceuticals during the fourth quarter valued at $43,000. Tower Research Capital LLC TRC purchased a new position in ARS Pharmaceuticals during the second quarter valued at $64,000. Wells Fargo & Company MN purchased a new position in ARS Pharmaceuticals during the second quarter valued at $64,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in ARS Pharmaceuticals by 352.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,105 shares of the company’s stock valued at $61,000 after acquiring an additional 8,652 shares in the last quarter. 68.16% of the stock is currently owned by institutional investors.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.